AstraZeneca announces that it hopes to have a new version of its vaccine against the COVID-19 list for use in the last quarter of this year, at a time when drug manufacturers are responding to emerging variants that could be more transmissible or resistant to existing vacancies.
The Anglo-Swedish company, which manufactures an undeveloped caravan at Oxford University, is working with the university’s scientists to adapt the caravan to the end, combining the new variants.
The investigators will start this work within a month, while detecting the first-time variants, Mene Pangalos, AstraZeneca’s biopharmaceutical research chief.
“We are moving fast and we are in the process of developing a series of versions against the variants, the ones that we choose to mediate on the clinical side”, said Pangalos in a conference call with periodicists.
For his part, the CEO of the pharmaceutical company, Pascal Soriot, defended the company’s efforts to de-roll and increase the production of the vaccine in the midst of European Union advertisements and a preliminary study, which generates doubts about the capacity of the injection to combat a COVID-19 variant first discovered in South Africa.
Although the launch of the AstraZeneca caravan has not been perfect, the regulators of various countries have discovered that it is safe and effective. The company will produce 100 million doses of this month, said Soriot.
Only a few vacancies have been authorized for the generalization of the sciences that will begin to unroll the past year, recalculated.
“Six million doses in February mean 100 million vacancies, which means tens of miles of serious infections that are avoided, and also mean miles of deaths that are avoided,” Soriot said.
Although the European Medicines Agency has approved the AstraZeneca vaccine for use by all 18-year-olds, some European countries — including France and Germany — recommended that 65-year-olds not receive the vaccine until their limited dates effectiveness in adult adults.